Clinical Data

VeriStrat® is a validated test that identifies patients as either VeriStrat Good or VeriStrat Poor.

The development and validation of VeriStrat was performed in a study using 460 patients in 8 different institutions spanning 4 countries.1 This study was published in the Journal of the National Cancer Institute (JNCI) and represents the first comprehensive and rigorously validated study using MALDI-TOF MS methods to classify patients for their clinical benefit from a molecularly targeted anticancer therapy.1

Below is a summary of the JNCI study. For the full article content click here.

Study Schema

Results from the study show that in a blinded validation, VeriStrat Poor patients have a higher rate of death as compared to VeriStrat Good patients after treatment with EGFR-TKIs.1

Survival Analysis of VeriStrat Validation Sets

This study also demonstrates that VeriStrat does not classify outcomes among patients not treated with EGFR-TKI therapy. In the control groups, there was no statistically significant difference in prognosis between VeriStrat Good and VeriStrat Poor groups. This demonstrates that VeriStrat is not merely prognostic of disease progression independent of EGFR-TKI treatment.

Control Results: Is VeriStrat Specific to EGFR-TKI Therapy?

In a subset analysis, VeriStrat identifies candidates for EGFR-TKI therapy that may otherwise be excluded based on patient characteristics, such as patients with a history of smoking or patients with squamous cell histology.

In patients with a history of smoking, VeriStrat Good patients showed a significantly better prognosis than VeriStrat Poor patients when treated with EGFR-TKI therapy.

Subset Analysis: VeriStrat Good and Poor—Survival in Patients With Smoking History Treated With EGFR-TKIs

In patients with squamous cell tumors, VeriStrat Good patients showed a significantly better prognosis than VeriStrat Poor patients when treated with EGFR-TKI therapy.

Subset Analysis: VeriStrat Good and Poor—Survival in Patients With Squamous Cell Tumors Treated With EGFR-TKIs

VeriStrat Scientific Presentation Download the VeriStrat Scientific Presentation (PDF)

References

1. Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst. 2007;99:838-846.